Expert Insights: Current and Emerging CAR T-Cell and Other Cellular Therapies for the Treatment of Patients with Hematologic Malignancies
Release Date: November 1, 2021
Expiration Date: October 31, 2022
Watch the experts who are actively engaged in the care of patients with hematologic malignancies as they reinforce key points and highlight the most clinically relevant data presented at the August 11th satellite symposia during the 2021 Pan Pacific Lymphoma Conference.
The target audience for this activity is community and academic medical oncologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with hematologic malignancies.
After participating in this activity, participants should be better able to:
- Discuss the rationale for using cellular-based therapies for patients with hematologic malignancies
- Evaluate the latest clinical trial data of current and emerging cellular therapies in patients with lymphoma and myeloma
- Assess practical approaches to the use of cellular therapy, including patient referral and adverse event management strategies
In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Bio Ascend. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The University of Nebraska Medical Center designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The University of Nebraska Medical Center designates this activity for up to .25 ANCC contact hours. Nurses should only claim credit for the actual time spent participating in the activity.
Method of Participation
There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must:
1) read the educational objectives and conflict of interest disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.
Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.
Faculty and Planning Committee Disclosures
As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planner and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.
This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.
The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.
Julie Vose, MD, MBA (Moderator)
Neumann M. and Mildred E. Harris Professor
Chief, Division of Oncology and Hematology
Department of Internal Medicine
University of Nebraska Medical Center | Omaha, Nebraska
Nina Shah, MD
Associate Professor, Department of Medicine
Helen Diller Family Comprehensive Cancer Center
University of California San Francisco | San Francisco, California
Julie Vose, MD, MBA
Consultant: Morphosy, AbbVie, Pharmacyclics, Astra-Zeneca
Nina Shah, MD
Consultant: Glaxo Smith-Kline. Amgen, Indapta Therapeutics, Sanofi, CareDX, Kite, Karyopharm, Oncopeptides, Celgene/Bristol Myers Squibb
Research Funding: Celgene/Bristol Myers Squibb, Janssen, Bluebird Bio, Sutro Biopharma, Teneobio, Poseida, Nektar
The following planning committee members have nothing to disclose:
UNMC: Brenda Ram, CMP, CHCP
Bio Ascend: Jennifer Bechan, CMP, HMCC; Dru Dace, PhD; Kraig Steubing
This activity is supported by educational grants from Bristol Myers Squibb and Legend Biotech.
Select the Continue button below to begin. You may return later if you are unable to complete the activity at this time.